Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

56%

5 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

5(55.6%)

N/A

2(22.2%)

Phase 2

2(22.2%)

9Total

Phase 4(5)

N/A(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03022019Not ApplicableTerminated

ReNovaCell in Non-segmental Vitiligo

Role: lead

NCT02548533Phase 4Terminated

Fractional Laser Assisted Topical Anesthesia

Role: lead

NCT03279757Phase 4Completed

Fractional Laser Assisted Delivery of Anesthetics IIIb

Role: lead

NCT02458417Phase 4Completed

Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients

Role: lead

NCT02938286Phase 4Completed

Fractional Laser Assisted Delivery of Anesthetics III

Role: lead

NCT02290717Not ApplicableWithdrawn

Fractional Laser in Combination With UVB Therapy in Vitiligo Patients

Role: lead

NCT02246179Phase 4Completed

Fractional Laser Assisted Delivery of Anesthetics

Role: lead

NCT01085279Phase 2Completed

Fractional Laser as Treatment Option for Various Pigment Disorders (Fractional-3)

Role: lead

NCT01083498Phase 2Completed

Fractional Laser as Treatment Option for Various Pigment Disorders

Role: lead

All 9 trials loaded